findmyKOL
Clinical trialNCT01938612CompletedPhase 1Interventional

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

SponsorAstraZenecaEnrollment269Advanced Solid Tumors
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase I, open-label, multicentre study of MEDI4736 administered intravenously with a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics in patients with advanced solid tumor followed by an expansion phase in patients with advanced solid tumors.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Japan
  • Research Site

    Beppu-shi, Japan

  • Research Site

    Chūōku, Japan

  • Research Site

    Kashiwa, Japan

  • Research Site

    Kitaadachi-gun, Japan

  • Research Site

    Kure-shi, Japan

  • Research Site

    Kōtoku, Japan

  • Research Site

    Matsuyama, Japan

  • Research Site

    Nagoya, Japan

  • Research Site

    Osaka, Japan

  • Research Site

    Sapporo, Japan

  • Research Site

    Sapporo, Japan

  • Research Site

    Sayama, Japan

  • Research Site

    Suita-shi, Japan

  • Research Site

    Sunto-gun, Japan

  • Research Site

    Takatsuki-shi, Japan

  • Research Site

    Yokohama, Japan

South Korea
  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

Taiwan
  • Research Site

    Tainan, Taiwan

  • Research Site

    Taipei, Taiwan

  • Research Site

    Taoyuan, Taiwan

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MEDI4736Tremelimumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
12 Sept 2013
Primary completion
1 Mar 2018
Completion
25 Nov 2020
Last update posted
12 Mar 2021
Registered enrollment
269
Registry id
NCT01938612
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.